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Abstract 
Background: Asthma is a chronic inflammatory disorder of airway that involves many cells and elements. Chronic 
inflammation caused by increase Airway hyperresponsiveness that cause recurrent episodic symptoms of breathless-
ness, wheezing, chest tightness and coughing, especially at night or early morning. Interleukin 17F is a cytokine that 
plays an important role in the pathophysiology of asthma attacks. Some studies show a variety of IL-17F roles in the 
pathogenesis of airway inflammation due to an allergic reaction.
Results: The study was conducted at the Prof. Dr. R. D. Kandou Manado Hospital, Indonesia. Samples were taken con-
tinuously until the number of meant samples was achieved. Blood samples were collected from 40 atopic asthmatic 
patients. From statistical analysis based on the hypothesis, there was positive correlation between mRNA levels of 
IL-17F and IL-17F in atopic asthmatic patient (p = 0.000 and r = 0.988).
Conclusions: According these data suggest that levels of mRNA IL-17F and IL17F might be useful parameters for the 
diagnosis of atopic asthma patient.
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Background
Asthma is a chronic inflammatory disorder of airways 
which involves many cells and elements. This chronic 
inflammation caused by increase airway hyperrespon-
siveness will manifest as recurrent episodic symptoms of 
breathlessness, chest tightness, wheezing and coughing, 
especially at night or early morning. Asthma is an impor-
tant and serious public health problem in many countries 
in the world. Asthma can be mild and doesn’t interfere 
with the activity, but it can also be persistent and disturb-
ing [1–3]. Atopic asthma or allergic asthma is asthma 
based on allergic reaction to the acquisition proper-
ties of atopy that found in family and characterized by 
increased total immunoglobulin E (IgE) or specific IgE. 
The prevalence of asthma in Indonesia ranged between 
5 and 7%, in global prevalence of asthma ranging from 7 
to 10%. According to data from the Center for Diseases 
Control and Prevention (CDC) National Asthma Control 
Program in United States 2010 there were 18.7 million 
adults suffer from Asthma and about nine people die 
from asthma each day [1, 2, 4, 5]. The prevalence of atopic 
asthma between 70 and 80% of people with asthma, and 
about 70–80% of people with asthma also accompanied 
with allergic rhinitis. The development of science and 
technology in the world is not entirely followed by the 
progress treatment for asthma, this has been shown by 
the data from many countries which show that number 
of asthma visit in emergency department, hospitaliza-
tions, morbidity and even mortality had increased [5]. 
In the developed country asthma exacerbations usually 
is caused by a viral infection, this is different from devel-
oping countries that exacerbations are usually caused by 
bacteria [1, 6].
Interleukin 17F is a cytokine that plays an important 
role in the pathophysiology of asthma attacks. Some stud-
ies has shown variety of IL-17F roles in the pathogenesis 
of airway inflammation due to an allergic reaction. Inter-
leukin 17F plays role in asthma attacks through various 
channels, such as affect the levels of respiratory tract 
neutrophil, stimulates mucus hypersecretion, respiratory 
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hyperreactivity, airway remodeling, and resistance from 
steroid [7–10]. Various gene variations associated with 
the occurrence of asthma and asthma severity, however 
the genetic role of mRNA IL-17F and IL-17F has not 
been fully understood [11]. This study shows that mRNA 
IL-17F levels and soluble IL-17F was higher in patients 
with asthma compared with the control group, although 




The study was conducted in allergy immunology clinic 
at Prof. Dr. R. D. Kandou Manado Hospital. After receiv-
ing approval from the hospital institutional review 
board, we obtained forty patients who attending allergy 
immunology clinic from April to October 2015. The 
sample selection is done by purposive sampling studies 
and cross-sectional study design. Informed consent was 
obtained from the patients.
Methods
The diagnosis of asthma is made by anamnesis history of 
asthma, physical examination and lung function measure-
ments using peak expiratory flow meter based on criteria 
of GINA. Atopy Diagnosis is based on total serum IgE lev-
els ≥100 IU/mL, measured using enzyme-linked immuno-
sorbent assay (ELISA) or with a positive skin test to house 
dust ≥1/mites [12]. Skin testing is done by using a 1 ml 
syringe with a 26 G needle sizes that are injected on the 
volar forearm within 1.5–2.5 cm space between allergens 
and scored after 15–20 min. Positive values are obtained 
when the ratio of allergen extract of house dust with his-
tamine as ≥0.5 from a positive control [13, 14]. Blood 
samples were drawn by vein puncture from the patients 
at least 5 ml of whole blood. Evaluation of serum interleu-
kin 17F blood and mRNA IL 17F samples were taken from 
all participants and centrifuged at 400g for 10 min. Serum 
samples were stored at −70 °C and then the sample trans-
ferred to laboratory for analysis. Serum levels of soluble 
IL-17F measured using commercially available enzyme-
linked immunosorbent assay kits (Catalog no. AB100557) 
according to the manufacturer’s instructions with detec-
tion range from 13.72 to 10.000 pg/ml [15]. Detection of 
mRNA gene IL-17F by using primary specific IL-17F for-
ward: 5′-GTGCCAGGAGGTAGTATGAAGC-3′; IL-17F 
reverse: 5′-ATGTCTTCCTTCCTTG AGCATT-3′. PCR 
Protocol: by doubling DNA with 94  °C cycle in 3  min, 
repeated 38 times with 54  °C (30  s). Detection GAPDH 
gene by using primary forward/sense: 5′-AGTCAACG-
GATTTGGTCGTATT-3′; Protocol PCR: 94 °C (10 min); 
32 cycle of 54  °C (30  s). Primary reverse/antisense; 
5′-ATGGGTGGAATCATATTGGAAC-3′ according to 
Tomomi Yajima’s protocol. QRT-PCR is using the Green 
QRT-PCR master mix kit, one step. This protocol is opti-
mized for the CFX Connect system, Biorad Laboratories 
instrument. The protocol is synced using instrument by 
changing coloring dilution according to the manual and 
following the producer company that is recommended for 
RT-PCR cycle program.
Passive coloring reference is put into the reaction, 
diluted 1:500. The solution, which contains coloring, 
was omitted from the light. Dilution 2x SYBR Green 
QRT-PCR master mix and stored on ice. Following 
early dilution master mix, the remaining unused part is 
stored in 4 °C with note, avoid solid–liquid cycle that is 
reduced. Reaction experiment is prepared by adding the 
following components. Preparing reagent mixture for 
reaction by using several components as follows. Rea-
gent mixture by taking the last volume 25 μl (including 
RNA experiment) 12.5  μl from 2x SYBR Green QRT-
PCR master mix added by 1 μl from early primary (opti-
mized concentration) and also 0.375  μl of reference 
coloring mixture from the first step (optional) along 
with 1.0  μl from RT/Rnase mixture of block enzyme 
with 50  μl of total volume reaction can also be used. 
Reaction is mixed slowly to prevent any bubble forma-
tion (not rotated), and then mixture is distributed into 
reaction tubes by adding 1  μl RNA of experiment into 
each reaction tubes, reaction is mixed slowly to prevent 
any bubble formation (not rotated). Reaction is cen-
trifuged shortly and placed into instrument and PCR 
program is ready to go by using Realtime PCR machine 
(CFX Connect system, Biorad Laboratories, Real Time 
PCR 96 well 0.1 ml, USA) [16, 17].
Data analysis
Our study was designed to have 80% power with a type I 
error 5% to detect significant correlation between mRNA 
levels of IL-17F and IL-17F in atopic asthmatic patient 
Mean and standard deviations for normally distributed 
data were calculated. Correlations were performed using 
Pearson’s coefficient. All statistics were performed on 
IBM SPSS version 20 statistical software.
Results
A total of 40 asthma patients have range of age: 
18–60  years old (43.9  ±  11.03  years) were divided 
into 15 male and 25 female. Hemoglobin range level 
12.4–17.9  mg  % (14.3  ±  1.1). Neutrophil levels range 
level 29.4–71.80% (52.1  ±  9.75). Total IgE range level 
144–6186% (1100.98 ± 1164). mRNA IL-I7F range level 
9.30–21.22 (14.18  ±  3.35) copy/μ. IL-17F range level 
71.40–1904 (916.94 ± 520) pg/ml (Table 1).
Among the subject in this study the mean level of IL-
17F on male subjects is higher than female subjects 
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1044.09 vs 840.66  pg/ml. While the mean level of IL17 
mRNA level was also higher among male subject.
Correlation between serum mRNA IL‑I7F with sIL‑17F levels 
in atopic asthma patient
Forty patients were enrolled with atopic asthma. All 
patient has sIL-17F range level of 71.40–1904  pg/ml 
(916.94 ± 520) and mRNA IL-I7F range level 9.30–21.22 
copy/μ (14.18  ±  3.35). Because of data mRNA IL-17F 
and sIL-17F were normally distributed, to evaluate cor-
relation between mRNA levels of sIL-17F and IL-17F 
Pearson correlation test was used. A p value of <0.05 was 
considered statistically significant. The results show that 
mRNA levels of IL-17F and sIL-17F were significantly 
up regulated in asthmatic patient (p < 0.000 and r 0.988) 
(Table 2). Scatter plot correlation between serum IL-17F 
with expression of mRNA IL-17F levels in atopic asthma 
F and patient is shown here (Fig. 1). These data suggest 
that the level of mRNA IL-17F and sIL-17F might be used 
as parameter for diagnosis of atopic asthma.
Discussion
Asthma is a disease which is usually diagnosed based 
on episodic symptoms and variable airway obstruction. 
It is also characterized by variable degrees of chronic 
inflammation and structural alterations in the airways 
[18–20]. This is a disease that usually affects kids and 
young adults at a higher frequency and is a cause of 
increased morbidity and mortality [21]. Asthma is no 
longer regarded as a pure inflammatory disease anymore 
rather it’s now regarded as a disease in which involved 
both inflammatory and structural changes [22]. These 
collective structural alterations known as airway remod-
eling, encompass various changes in lot of aspect of air-
way such as composition, content, and organization of 
many cellular and molecular constituents [23]. Airway 
remodeling encompasses lot of aspects such as epithelial 
detachment, goblet cell hyperplasia, subepithelial thick-
ening, hyperplasia and hypertrophy of airway smooth 
muscle, bronchial gland enlargement, angiogenesis, 
and alterations in the extracellular matrix components. 
These changes is influenced by complicated network of 
cytokines [23, 24]. The clarification of the modulation 
of this cytokine network could contribute to the under-
standing of asthma pathogenesis and development of 
new therapeutic strategies. Asthma is a chronic inflam-
matory disorder of the airways which is heavily driven by 
T cell [9]. Both T helper (Th)2 and Th1 lymphocytes, play 
an important role in the pathophysiology of asthma.
The over production of T helper (Th)2 cytokines (IL-
4, IL-5, IL-9 and IL-13) in the asthmatic airways is well 
defined, and recent studies indicate that IFN-γ which is 
produced by Th1 might responsible for severe airway 
inflammation. Recently, a separate T cell lineage, called 
Th17 cells or inflammatory T cells, producing IL-17A (or 
IL-17), has been identified. IL-17 is a 20 to 30-kD pro-
tein, the original member of the IL-17 cytokine family 
was first identified in 1993 and initially recognized for its 
Table 1 Baseline characteristics of subject who suffer from  
atopic asthma




Age 23 60 43.90 1.745 11.038
Haemoglo-
bin (mg%)
12.40 17.90 14.3500 0.18828 1.19078
Neutrophil 29.40 71.80 52.1555 1.54234 9.75458
IgE total 144 6186 1100.97 184.149 1164.662
IL-17F  
(pg/ml)
71.40 1904.03 916.9440 82.28120 520.39203
mRNA IL17F 
(pg/ml)
9.3 21.22 14.1822 53,072 3.35657
Table 2 The mean level of  mRNA-IL17F and  sIL-17F 
among male and female subjects who suffered from Atopy 
Asthma
N Mean mRNA‑17F Mean sIL‑17F level
Male 15 14.95 1044.09
Female 25 13.72 840.66
Fig. 1 Scatter plot correlation between mRNA IL-17F levels and sIL-
I7F in atopic asthma patient
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similarity to a sequence belonging to the open reading 
frame 13 of Herpes virus saimiri. Five additional mem-
bers, IL-17B, IL-17C, IL-17D, IL-17E (also called IL-25), 
and IL-17F, were discovered within a short period of 
time since 2000 to 2002. Th17 cell was thought to play an 
important role in the pathophysiology of atopic asthma 
[8, 10, 22]. IL-17F has an important role in the recruit-
ment of neutrophils and in asthmatic patients, studies 
has shown that there is an increase of expression of IL-
17F in the sputum, lung, bronchoalveolar lavage fluids 
and peripheral blood of asthmatic patients [17].
Previous study discovered that activated CD4 T cell, 
basophils and mast cell show increase in the expression 
of IL-17F. These three cell is an important regulatory cell 
types that play important role for regulating allergic air-
way inflammation in bronchial asthma. While IL-17F 
which is produced by Th17 cell constituting independ-
ent  CD4+ T cell subset [18]. Among the IL-17 cytokine 
family members, IL-17F shows the highest amino acid 
sequence homology (50%) to IL-17A, while only 10–30% 
sequence identity is seen between IL-17A and the other 
family members [7]. The IL-17F gene was discovered in 
2001, and located on chromosome 6p12. IL17A and IL17F 
gene was located in same chromosome region. How-
ever, IL 17F seems to function differently from IL-17A in 
immune response and disease [25]. IL-17F is derived from 
activated CD4+ cells, basophil and mast cell which are 
important regulatory cell types for allergic airway inflam-
mation. Increased expression of IL-17F after segmental 
allergen challenge is seen in the bronchoalveolar lavage 
cells from asthmatic person. IL-17 F is expressed in both 
epithelium and inflammatory infiltrates [26, 27]. Immu-
nocytochemistry showed that IL-17F positive cells in the 
subepithelial component and epithelium are significantly 
elevated in severe asthma compared with healthy and 
mild asthmatic subjects [27]. Additionally, an increased 
expression of epithelial IL-17F was correlated with disease 
severity. Another recent study demonstrated that asth-
matic patients have a significantly higher level of serum 
IL-17 F protein as compared to that of healthy subjects 
[28]. This implies that IL-17F can be used as a clinical 
biomarker for asthma diagnosis and management. IL-17F 
was thought to have a role in the enhancement of allergic 
airway inflammation. This role was hypothesized due to 
finding that IL-17F has been shown to be able to induce 
pulmonary neutrophilia and produce an additive effect on 
antigen-induced allergic inflammatory response. IL-17F is 
also able to induce several cytokines and chemokines in 
bronchial epithelial cells, vein endothelial cells and fibro-
blast. IL-17F will affects the eosinophil, to induced several 
cytokines and chemokines such as IL-1β, IL-6, IL-8, GRO 
α, and MIP-1 β.
Another evidence for the role of sIL-17F in the patho-
genesis of asthma is provided by the increase of IL-
17mRNA in airways of mouse model of asthma and 
also in the sputum of asthmatic patients. Increase of IL-
17mRNA is heavily correlated with number of neutro-
phils and consistent with its mRNA expression [29, 30]. 
Research demonstrated that in inflamed bronchi induced 
by allergen inhalation the IL-17F mRNA expression will 
be upregulated, and that sIL-17F differentially regulates 
bronchial influx of granulocytes induced by allergen both 
after single as well as after repeated allergen inhalation 
by sensitized mice. Rapid production of mRNA for IL-
17F after allergen provocation suggested the presence of 
sIL-17F producing memory T cell population in inflamed 
airways.
Conclusions
This study show that mRNA levels of IL-17F and sIL-17F 
has significantly correlation in atopic asthmatic patient 
(p = 0.000 and r = 0.988). These data suggest that the lev-
els of mRNA IL17F and sIL17F might be useful param-
eters for the diagnosis of atopic asthma patient.
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